Literature DB >> 10692903

Management of acute bursitis: outcome study of a structured approach.

I M Stell1.   

Abstract

In patients with septic bursitis the indications for admission and surgical intervention remain unclear, and practice has varied widely. The effectiveness of a conservative outpatient based approach was assessed by an outcome study in a prospective case series. Consecutive patients attending an emergency department with acute swelling of the olecranon or prepatellar bursa were managed according to a structured approach, subjective and objective outcomes being assessed after two to three days, and subsequently as required until clinical discharge. Long-term outcomes were assessed by telephone follow-up for up to eighteen months. 47 patients were included in the study: 22 had septic bursitis, 15 of the olecranon bursa and 7 of the prepatellar bursa. The mean visual analogue pain scores of those with septic bursitis improved from 4.8 at presentation to 1.7 at first follow-up for olecranon bursitis, and from 3.8 to 2.7 for prepatellar bursitis. Symptoms improved more slowly for patients with non-septic bursitis. No patients were admitted initially, but 2 were admitted (two days each) after the first follow-up appointment. One patient had incision and drainage on the third attendance, and 3 patients developed discharging sinuses, which all healed spontaneously. All patients made a good long-term symptomatic recovery and all could lean on the elbow or kneel by the end of the follow-up period. The management protocol, with specific criteria for admission and surgical intervention, thus produced good results with little need for operation or admission.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10692903      PMCID: PMC1297391          DOI: 10.1177/014107689909201006

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  14 in total

1.  Simple tests for septic bursitis: comparative study.

Authors:  I M Stell; W R Gransden
Journal:  BMJ       Date:  1998-06-20

Review 2.  Measurement of feelings using visual analogue scales.

Authors:  R C Aitken
Journal:  Proc R Soc Med       Date:  1969-10

3.  Long-term follow-up of corticosteroid injection for traumatic olecranon bursitis.

Authors:  P S Weinstein; J J Canoso; J R Wohlgethan
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

4.  Treatment of septic olecranon and prepatellar bursitis with percutaneous placement of a suction-irrigation system. A report of 12 cases.

Authors:  J M Knight; J C Thomas; R C Maurer
Journal:  Clin Orthop Relat Res       Date:  1986-05       Impact factor: 4.176

5.  Predisposing factors, bacteriology and antibiotic therapy in 35 cases of septic bursitis.

Authors:  B Söderquist; S A Hedström
Journal:  Scand J Infect Dis       Date:  1986

6.  Septic bursitis.

Authors:  G R Thompson; B M Manshady; J J Weiss
Journal:  JAMA       Date:  1978-11-17       Impact factor: 56.272

7.  Septic bursitis in immunocompromised patients.

Authors:  R A Roschmann; C L Bell
Journal:  Am J Med       Date:  1987-10       Impact factor: 4.965

8.  Septic bursitis in the prepatellar and olecranon bursae: an analysis of 25 cases.

Authors:  G Ho; A D Tice; S R Kaplan
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

9.  Septic bursitis: presentation, treatment and prognosis.

Authors:  D A Raddatz; G S Hoffman; W A Franck
Journal:  J Rheumatol       Date:  1987-12       Impact factor: 4.666

10.  Comparison of nonseptic and septic bursitis. Further observations on the treatment of septic bursitis.

Authors:  G Ho; A D Tice
Journal:  Arch Intern Med       Date:  1979-11
View more
  10 in total

Review 1.  Olecranon bursitis: a systematic overview.

Authors:  John R Blackwell; Bruce A Hay; Alexander M Bolt; Stuart M Hay
Journal:  Shoulder Elbow       Date:  2014-05-06

2.  A Randomized Trial Among Compression Plus Nonsteroidal Antiinflammatory Drugs, Aspiration, and Aspiration With Steroid Injection for Nonseptic Olecranon Bursitis.

Authors:  Joon Yub Kim; Seok Won Chung; Joo Hak Kim; Jae Hong Jung; Gwang Young Sung; Kyung-Soo Oh; Jong Soo Lee
Journal:  Clin Orthop Relat Res       Date:  2015-10-13       Impact factor: 4.176

3.  Clinical characteristics and outcomes of septic bursitis.

Authors:  Sarah B Lieber; Mary Louise Fowler; Clara Zhu; Andrew Moore; Robert H Shmerling; Ziv Paz
Journal:  Infection       Date:  2017-05-29       Impact factor: 3.553

Review 4.  [Treatment of traumatic lesions of the bursa olecrani and chronic bursitis olecrani].

Authors:  D Saul; K Dresing
Journal:  Oper Orthop Traumatol       Date:  2017-06       Impact factor: 1.154

5.  Evaluation of current treatment regimens for prepatellar and olecranon bursitis in Switzerland.

Authors:  S F Baumbach; H Wyen; C Perez; K-G Kanz; I Uçkay
Journal:  Eur J Trauma Emerg Surg       Date:  2012-11-08       Impact factor: 3.693

6.  Endoscopic treatment of prepatellar bursitis.

Authors:  Yu-Chih Huang; Wen-Lin Yeh
Journal:  Int Orthop       Date:  2010-06-04       Impact factor: 3.075

7.  Management of septic and aseptic prepatellar bursitis: a systematic review.

Authors:  Oliver S Brown; T O Smith; T Parsons; M Benjamin; C B Hing
Journal:  Arch Orthop Trauma Surg       Date:  2021-03-15       Impact factor: 2.928

8.  Endoscopic versus Open Bursectomy for Prepatellar and Olecranon Bursitis.

Authors:  Gokhan Meric; Serdar Sargin; Aziz Atik; Aydin Budeyri; Ali Engin Ulusal
Journal:  Cureus       Date:  2018-03-27

9.  Effects of Inflammatory Disease on Clinical Progression and Treatment of Ischiogluteal Bursitis: A Retrospective Observational Study.

Authors:  Y H Roh; S J Yoo; Y H Choi; H C Yang; K W Nam
Journal:  Malays Orthop J       Date:  2020-11

10.  Efficacy of empiric antibiotic management of septic olecranon bursitis without bursal aspiration in emergency department patients.

Authors:  Adrian Beyde; Alexa L Thomas; Kristina M Colbenson; Benjamin J Sandefur; Imtithal Kisirwan; Aidan F Mullan; Shawn W O'Driscoll; Ronna L Campbell
Journal:  Acad Emerg Med       Date:  2021-11-09       Impact factor: 5.221

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.